Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Haoxiang Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6302-0901; OpenAlex author ID A5100765848. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers

Papers 9

  1. Clinicopathological features and survival outcomes of patients with different distant and lymph node metastasis in pancreatic cancer. Last author DOI 10.1007/s12672-026-04680-3↗
  2. Matrix stiffness induces Ca2+-DCLK1-PIP5K1A mechanotransduction as a context-specific amplifier in pancreatic cancer progression and chemotherapy resistance. Co-author DOI 10.1186/s40164-026-00756-6↗
  3. SenExo-cCCT2 Reprograms Senescence Response and Anti-Tumor Immunity Following FOLFIRINOX Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202508431↗
  4. Targeting CLK1/SRSF7 axis-dependent alternative splicing sensitizes pancreatic ductal adenocarcinoma to chemotherapy and immunotherapy. Co-author DOI 10.1016/j.drup.2025.101292↗
  5. TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis. Co-author DOI 10.1158/0008-5472.can-24-4784↗
  6. Single dual-specific anti-PD-L1/TGF-β antibody synergizes with chemotherapy as neoadjuvant treatment for pancreatic ductal adenocarcinoma: a preclinical experi… Co-author DOI 10.1097/js9.0000000000001226↗
  7. METTL3 promotes pancreatic cancer proliferation and stemness by increasing stability of ID2 mRNA in a m6A-dependent manner. First author DOI 10.1016/j.canlet.2023.216222↗
  8. Hyperglycemia Enhances Immunosuppression and Aerobic Glycolysis of Pancreatic Cancer Through Upregulating Bmi1-UPF1-HK2 Pathway. First author DOI 10.1016/j.jcmgh.2022.07.008↗
  9. A nomogram predicting overall survival for metastatic pancreatic cancer: SEER database analysis Co-author DOI 10.21203/rs.3.rs-1410601/v1↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jiaoshun Chen · 5 shared papers, 2022–2026 · strength 1.04
  2. Tao Yin · 5 shared papers, 2022–2026 · strength 1.04
  3. Cheng‐Yu Liao · 3 shared papers, 2025 · strength 0.60
  4. Zuwei Wang · 3 shared papers, 2025 · strength 0.60
  5. Shun‐Cang Zhu · 3 shared papers, 2025 · strength 0.60
  6. Yongding Wu · 3 shared papers, 2025 · strength 0.60
  7. Shi Chen · 3 shared papers, 2025 · strength 0.60
  8. Chengke Xie · 2 shared papers, 2025 · strength 0.40
  9. Ge Li · 2 shared papers, 2025 · strength 0.40
  10. Yu Pan · 2 shared papers, 2025 · strength 0.40
  11. Shihong Wu · 2 shared papers, 2022–2023 · strength 0.34
  12. Heshui Wu · 2 shared papers, 2022 · strength 0.32
  13. Chuanbing Zhao · 1 shared paper, 2026 · strength 0.32
  14. Jianlin Lai · 1 shared paper, 2026 · strength 0.29
  15. Hong-Yi Lin · 1 shared paper, 2025 · strength 0.20
  16. Chun Zhang · 1 shared paper, 2025 · strength 0.20
  17. Ge Li · 1 shared paper, 2025 · strength 0.20
  18. Yifeng Tian · 1 shared paper, 2025 · strength 0.20
  19. Kun Liu · 1 shared paper, 2022 · strength 0.16
  20. Taoyu Chen · 1 shared paper, 2022 · strength 0.16
  21. Hehe Li · 1 shared paper, 2022 · strength 0.15
  22. Zibo Meng · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.